Best Practice and Research. Clinical Haematology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Myeloid disorders after autoimmune disease
Publication date: Available online 7 February 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Prajwal Boddu, Amer M. ZeidanABSTRACTAutoimmune diseases (ADs) are associated with an increased risk not only of lymphoproliferative disorders but also of myeloid malignancies. The excess risk of myelodysplastic syndromes and/or acute myeloid leukemia is observed across several AD types, including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disorders, multiple sclerosis, among others. The risk of developing myeloid neoplasms (MNs) is dependent on several variables, including the speci...
Source: Best Practice and Research Clinical Haematology - February 8, 2019 Category: Hematology Source Type: research
Therapy-associated leukemic Transformation in Myeloproliferative Neoplasms – What do we know?
Publication date: Available online 8 February 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Danielle Cuthbert, Brady Lee SteinAbstractMyeloproliferative Neoplasms (MPNs) are a group of progressive diseases that share a common pathogenesis, clinical and laboratory features, as well as a spontaneous risk of secondary AML. Certain MPN therapies have been associated with an increased risk of leukemic conversion, with robust data highlighting the highest rates with 32P, chlorambucil, and pipobroman. Herein, we review risk factors for leukemic transformation, including therapy-related MPN-BP, with a focus o...
Source: Best Practice and Research Clinical Haematology - February 8, 2019 Category: Hematology Source Type: research
Stem Cell Damage after Chemotherapy- Can We Do Better?
Publication date: Available online 6 February 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Joy Tang, Nan Zhu, Sridhar Rao, Karen-Sue CarlsonABSTRACTTherapy-related myeloid neoplasms are unintended and unwanted complications of cytotoxic chemotherapy and radiation. Unlike other environmental toxin-induced malignancies, exposure to the inciting agent is required to eradicate a primary and life-threatening cancer. In this review, we will focus on the biochemical mechanisms that lead to therapy-induced myeloid malignancy. This includes discussion of known mechanisms by which cytotoxic chemotherapy and ra...
Source: Best Practice and Research Clinical Haematology - February 6, 2019 Category: Hematology Source Type: research
Editorial Board / Aims & Scope
Publication date: December 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 4Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - November 21, 2018 Category: Hematology Source Type: research
What biologic factors predict for transformation to AML?
Publication date: Available online 23 October 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Rafael BejarTransformation of myelodysplastic syndromes (MDS) into secondary acute myeloid leukemia (sAML) is defined by an arbitrary boundary of >20% bone marrow blasts but does not necessarily reflect a defined biological transition. The more obvious distinction lies between MDS patients that have an isolated bone marrow failure phenotype and those with excess blasts. Subtyping of MDS might be more accurately stratified into clonal cytopenias and oligoblastic leukemias, using the degree of dysplasia and blast...
Source: Best Practice and Research Clinical Haematology - October 24, 2018 Category: Hematology Source Type: research
Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Mark R. LitzowAbstractBefore the advent of tyrosine kinase inhibitors (TKIs), Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and c...
Source: Best Practice and Research Clinical Haematology - October 17, 2018 Category: Hematology Source Type: research
Can one target T-cell ALL?
Publication date: Available online 17 October 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Adolfo FerrandoProgress in our understanding of the central genes, pathways, and mechanisms in the pathobiology of T-cell acute lymphoblastic leukemia (T-ALL) has identified key drivers of the disease, opening new opportunities for therapy. Drugs targeting highly prevalent genetic alterations in NOTCH1 and CDKN2A are being explored, and multiple other targets with readily available therapeutic agents, and immunotherapies are being investigated. The molecular basis of T-ALL is reviewed here and potential targets...
Source: Best Practice and Research Clinical Haematology - October 17, 2018 Category: Hematology Source Type: research
Can haploidentical transplantation meet all patients' needs?
Publication date: Available online 21 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Daniel WeisdorfAbstractAllotransplantation in the absence of an HLA-matched sibling donor can offer numerous donor options including unrelated donor and umbilical cord blood grafting. Recently, haploidentical transplantation has exploded in popularity and worldwide use following the application of post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis. Various approaches, disease states, conditioning intensities and supportive care advances have improved all these choices without demonstrable superiorit...
Source: Best Practice and Research Clinical Haematology - October 16, 2018 Category: Hematology Source Type: research
Should immunologic strategies be incorporated into frontline ALL therapy?
Publication date: Available online 25 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Cecilie Utke Rank, Wendy StockAbstractSurvival rates in adult patients with acute lymphoblastic leukemia (ALL) have markedly improved during the past decade. The one-size-fits-all-ages approach has been replaced with adaptation of pediatric-inspired treatment protocols for younger adults. Yet different treatment strategies for older patients are needed due to chemotherapy-related toxicities. A new era of immunotherapy has arrived, offering opportunities for targeted treatments for ALL subtypes. While CD20 tar...
Source: Best Practice and Research Clinical Haematology - October 5, 2018 Category: Hematology Source Type: research
Identifying patients with genetic predisposition to acute myeloid leukemia
Publication date: Available online 25 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Ellyn Obrochta, Lucy A. GodleyAbstractGermline syndromes in myeloid leukemias are being discovered increasingly in patients, and their identification is essential for proper medical management to yield positive health outcomes for patients and their families. There needs to be a greater appreciation of germline predisposition driving the development of hematologic malignancies within the field of myeloid malignancies. Characterization of the influence of germline mutations on the development of myeloid malign...
Source: Best Practice and Research Clinical Haematology - October 5, 2018 Category: Hematology Source Type: research
Is it time to routinely incorporate MRD into practice?
Publication date: Available online 21 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Farhad RavandiInterest in detecting minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) has been increasing, but numerous issues need to be addressed if MRD assessment is to be routinely incorporated into practice. Assays, their reliability, standardization, and availability all must be considered, and a strategy developed to eradicate residual leukemia. This paper reviews some issues surrounding the routine incorporation of MRD assessment into practice. (Source: Best Practice and Resear...
Source: Best Practice and Research Clinical Haematology - September 22, 2018 Category: Hematology Source Type: research
Why is a 3-year NRM following allogeneic transplantation still stuck at approximately 20%?
Publication date: Available online 21 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): John BarrettWhether and when to recommend an allogeneic stem cell transplant (SCT) for a patient with leukemia is a treatment decision that rests on determining whether the transplant or non-transplant option carries the greatest probability of 3-5-year survival. While SCT confers a greater possibility of leukemia cure, the decision to transplant has to be made in the light of the high chance of treatment-related mortality (TRM) that follows the allograft. Here we identify that current estimates of a 20% 3-ye...
Source: Best Practice and Research Clinical Haematology - September 22, 2018 Category: Hematology Source Type: research
Can haploidentical transplantation meet all patients’ needs?
Publication date: Available online 21 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Daniel WeisdorfAllotransplantation in the absence of an HLA-matched sibling donor can offer numerous donor options including unrelated donor and umbilical cord blood grafting. Recently, haploidentical transplantation has exploded in popularity and worldwide use following the application of post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis. Various approaches, disease states, conditioning intensities and supportive care advances have improved all these choices without demonstrable superiority of one...
Source: Best Practice and Research Clinical Haematology - September 22, 2018 Category: Hematology Source Type: research
Patterns of mutations in TP53 mutated AML
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): John S. WelchTP53 mutated acute myeloid leukemia (AML) responds poorly to chemotherapy and has a short overall survival rate with a median of 5-9 months. Poor outcomes in TP53 mutated AML following chemotherapy have been observed and treatment options remain limited, although the presence of TP53 mutations alone should not be a barrier to therapy. Decitabine is emerging as an alternative treatment option for patients with TP53 mutated AML, although the agent has not been associated with deep molecular remissi...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research
What FLT3 inhibitor holds the greatest promise?
Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Richard M. StoneAbstractDetermining which FLT3 inhibitor holds the greatest promise is a difficult task, as the drugs vary according to potency, specificity, protein-binding, drug interactions, and side effect profile. The best choice depends on when in the course of the disease the inhibitor will be used. Moreover, as the results of ongoing trials become available, newer agents could supplant former ‘best’ drugs. This paper reviews FLT3 inhibitors in combination with chemotherapy early in the disease in ...
Source: Best Practice and Research Clinical Haematology - September 21, 2018 Category: Hematology Source Type: research
